Is Ado-trastuzumab emtansine a targeted drug?

Ado-trastuzumab emtansine consists of two anti-cancer drugs, a HER2-targeted drug therapy (trastuzumabtrastuzumab) and a chemotherapy drug (emtansine DM1). It is used to treat patients with HER2+ breast cancer. Trastuzumab is given by intravenous injection in a doctor's office, clinic, or hospital. When a patient receives trastuzumab, the patient is receiving both drugs at the same time. Doctors will use specific tests to determine if a patient is a candidate for trastuzumab treatment.

Cells in HER2+ breast cancer grow and divide too quickly because they have too many HER2 receptors. Targeted drug therapies find and attack specific types of cancer cells and may cause less damage to healthy cells. Common serious side effects can still occur with targeted drug treatments. Trastuzumab finds and attaches to receptors on the outside of HER2+ cells. Here, it works by stopping cell growth and enhancing the immune system's effectiveness in killing cancer cells. Trastuzumab also enters cells and breaks down to release chemotherapy drugs. Chemotherapy works inside cells, causing them to die. Trastuzumab is technically known as a HER2-targeting antibody-drug conjugate.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.